Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

PERL in Diabetes Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data.

Afkarian M, Polsky S, Parsa A, Aronson R, Caramori ML, Cherney DZ, Crandall JP, de Boer IH, Elliott TG, Galecki AT, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Lingvay I, Maahs DM, McGill JB, Molitch ME, Perkins BA, Pop-Busui R, Pragnell M, Rosas SE, Rossing P, Senior P, Sigal RJ, Spino C, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M, Doria A; PERL Study Group.

Diabetes Care. 2019 Jun 11. pii: dc190342. doi: 10.2337/dc19-0342. [Epub ahead of print]

PMID:
31186299
2.

Building a collaboration to improve surgical research through EORTC/ESSO 1409-CLIMB study: A prospective liver metastasis database with an integrated quality assurance program.

Caballero C, Burock S, Carrion-Alvarez L, Nilsson H, Ruers T, Senellart P, Rivoire M, Stattner S, Primavesi F, Troisi R, Gruenberger T, Heil J, Schnitzbauer AA, Rahbari NN, Swijnenburg RJ, Malik H, Protic M, Kataoka K, Mauer M, Ducreux M, Poston G, Evrard S.

Eur J Surg Oncol. 2019 May 30. pii: S0748-7983(19)30466-4. doi: 10.1016/j.ejso.2019.05.028. [Epub ahead of print]

PMID:
31171479
3.

Changes in Albuminuria But Not GFR are Associated with Early Changes in Kidney Structure in Type 2 Diabetes.

Looker HC, Mauer M, Saulnier PJ, Harder JL, Nair V, Boustany-Kari CM, Guarnieri P, Hill J, Esplin CA, Kretzler M, Nelson RG, Najafian B.

J Am Soc Nephrol. 2019 Jun;30(6):1049-1059. doi: 10.1681/ASN.2018111166.

PMID:
31152118
5.

Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.

Ramaswami U, Bichet DG, Clarke LA, Dostalova G, Fainboim A, Fellgiebel A, Forcelini CM, An Haack K, Hopkin RJ, Mauer M, Najafian B, Scott CR, Shankar SP, Thurberg BL, Tøndel C, Tylki-Szymanska A, Bénichou B, Wijburg FA.

Mol Genet Metab. 2019 May;127(1):86-94. doi: 10.1016/j.ymgme.2019.03.010. Epub 2019 Apr 3.

6.

Cancer events in Belgian nursing home residents: An EORTC prospective cohort study.

Wildiers H, Mauer M, Elseviers M, De Wolf J, Hatse S, Hamaker M, Buntinx F, De Lepeleire J, Uytterschaut G, Falandry C, Tryfonidis K, Janssen-Heijnen M.

J Geriatr Oncol. 2019 Mar 18. pii: S1879-4068(19)30001-3. doi: 10.1016/j.jgo.2019.03.005. [Epub ahead of print]

7.

Genetic Determinants of Glycated Hemoglobin in Type 1 Diabetes.

Syreeni A, Sandholm N, Cao J, Toppila I, Maahs DM, Rewers MJ, Snell-Bergeon JK, Costacou T, Orchard TJ, Caramori ML, Mauer M, Klein BEK, Klein R, Valo E, Parkkonen M, Forsblom C, Harjutsalo V, Paterson AD; DCCT/EDIC Research Group, Groop PH; FinnDiane Study Group.

Diabetes. 2019 Apr;68(4):858-867. doi: 10.2337/db18-0573. Epub 2019 Jan 23.

PMID:
30674623
8.

Inappropriate Grading of Adverse Events in Cancer Clinical Trials-Reply.

Cristina V, Mauer M, Wagner AD.

JAMA Oncol. 2018 Dec 13. doi: 10.1001/jamaoncol.2018.5871. [Epub ahead of print] No abstract available.

PMID:
30543369
9.

Urine inositol pentakisphosphate 2-kinase and changes in kidney structure in early diabetic kidney disease in type 1 diabetes.

Looker HC, Merchant ML, Rane MJ, Nelson RG, Kimmel PL, Rovin BH, Klein JB, Mauer M; CKD Biomarkers Consortium.

Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1484-F1492. doi: 10.1152/ajprenal.00183.2018. Epub 2018 Aug 22.

PMID:
30132343
10.

Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071).

Moehler M, Schad A, Maderer A, Atasoy A, Mauer ME, Caballero C, Thomaidis T, John JMM, Lang I, Van Cutsem E, Freire J, Lutz MP, Roth A; EORTC Gastrointestinal Tract Cancer Group.

Cancer Chemother Pharmacol. 2018 Oct;82(4):733-739. doi: 10.1007/s00280-018-3667-8. Epub 2018 Aug 13.

PMID:
30105460
11.

Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.

Stocker G, Hacker UT, Fiteni F, John Mahachie J, Roth AD, Van Cutsem E, Peeters M, Lordick F, Mauer M.

Eur J Cancer. 2018 Aug;99:49-57. doi: 10.1016/j.ejca.2018.05.004. Epub 2018 Jun 15.

PMID:
29906734
12.

Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group.

Cristina V, Mahachie J, Mauer M, Buclin T, Van Cutsem E, Roth A, Wagner AD.

JAMA Oncol. 2018 Jul 1;4(7):1003-1006. doi: 10.1001/jamaoncol.2018.1080. No abstract available.

13.

Role of Kidney Biopsies for Biomarker Discovery in Diabetic Kidney Disease.

Looker HC, Mauer M, Nelson RG.

Adv Chronic Kidney Dis. 2018 Mar;25(2):192-201. doi: 10.1053/j.ackd.2017.11.004. Review.

14.

Fabry disease revisited: Management and treatment recommendations for adult patients.

Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, Waldek S, Wallace E, Weidemann F, Wilcox WR.

Mol Genet Metab. 2018 Apr;123(4):416-427. doi: 10.1016/j.ymgme.2018.02.014. Epub 2018 Feb 28. Review.

15.

Urinary IgG4 and Smad1 Are Specific Biomarkers for Renal Structural and Functional Changes in Early Stages of Diabetic Nephropathy.

Doi T, Moriya T, Fujita Y, Minagawa N, Usami M, Sasaki T, Abe H, Kishi S, Murakami T, Ouchi M, Ichien G, Yamamoto K, Ikeda H, Koezuka Y, Takamatsu N, Shima K, Mauer M, Nagai K, Tominaga T.

Diabetes. 2018 May;67(5):986-993. doi: 10.2337/db17-1043. Epub 2018 Feb 28.

16.

Uric Acid and Diabetic Nephropathy Risk.

Mauer M, Doria A.

Contrib Nephrol. 2018;192:103-109. doi: 10.1159/000484284. Epub 2018 Jan 23. Review.

PMID:
29393137
17.

White blood cell fractions correlate with lesions of diabetic kidney disease and predict loss of kidney function in Type 2 diabetes.

Wheelock KM, Saulnier PJ, Tanamas SK, Vijayakumar P, Weil EJ, Looker HC, Hanson RL, Lemley KV, Yee B, Knowler WC, Hadjadj S, Najafian B, Mauer M, Nelson RG.

Nephrol Dial Transplant. 2017 Dec 1;32(12):2145. doi: 10.1093/ndt/gfx303. No abstract available.

PMID:
29088394
18.

White blood cell fractions correlate with lesions of diabetic kidney disease and predict loss of kidney function in Type 2 diabetes.

Wheelock KM, Saulnier PJ, Tanamas SK, Vijayakumar P, Weil EJ, Looker HC, Hanson RL, Lemley KV, Yee B, Knowler WC, Hadjadj S, Najafian B, Mauer M, Nelson RG.

Nephrol Dial Transplant. 2018 Jun 1;33(6):1001-1009. doi: 10.1093/ndt/gfx231.

PMID:
28992267
19.

Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment.

Mauer M, Sokolovskiy A, Barth JA, Castelli JP, Williams HN, Benjamin ER, Najafian B.

J Med Genet. 2017 Nov;54(11):781-786. doi: 10.1136/jmedgenet-2017-104826. Epub 2017 Jul 29.

20.

Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus.

Wheelock KM, Cai J, Looker HC, Merchant ML, Nelson RG, Fufaa GD, Weil EJ, Feldman HI, Vasan RS, Kimmel PL, Rovin BH, Mauer M, Klein JB; CKD Biomarkers Consortium.

PLoS One. 2017 Jul 10;12(7):e0180964. doi: 10.1371/journal.pone.0180964. eCollection 2017.

21.

VetCompanion: response and clarifications.

Mauer MP, Garcia J.

J Med Libr Assoc. 2017 Jul;105(3):293-294. doi: 10.5195/jmla.2017.187. Epub 2017 Jul 1. No abstract available.

22.

Serum cystatin C in youth with diabetes: The SEARCH for diabetes in youth study.

Kanakatti Shankar R, Dolan LM, Isom S, Saydah S, Maahs DM, Dabelea D, Reynolds K, Hirsch IB, Rodriguez BL, Mayer-Davis EJ, Marcovina S, D'Agostino R Jr, Mauer M, Mottl AK.

Diabetes Res Clin Pract. 2017 Aug;130:258-265. doi: 10.1016/j.diabres.2017.06.010. Epub 2017 Jun 12.

23.

Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.

Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Folprecht G, Van Cutsem E, Ducreux M, Nordlinger B; European Organisation for Research and Treatment of Cancer (EORTC); Gastro-Intestinal Tract Cancer Group; Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG).

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx015.

24.

Outcomes and Risk Factors for Graft Loss: Lessons Learned from 1,056 Pediatric Kidney Transplants at the University of Minnesota.

Chinnakotla S, Verghese P, Chavers B, Rheault MN, Kirchner V, Dunn T, Kashtan C, Nevins T, Mauer M, Pruett T; MNUM Pediatric Transplant Program.

J Am Coll Surg. 2017 Apr;224(4):473-486. doi: 10.1016/j.jamcollsurg.2016.12.027. Epub 2017 Feb 27.

PMID:
28254584
25.

Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG.

Kataoka K, Kinoshita T, Moehler M, Mauer M, Shitara K, Wagner AD, Schrauwen S, Yoshikawa T, Roviello F, Tokunaga M, Boku N, Ducreux M, Terashima M, Lordick F; EORTC GITCG Group and JCOG SCGC Group.

Gastric Cancer. 2017 Sep;20(5):904-912. doi: 10.1007/s10120-017-0696-7. Epub 2017 Feb 1.

PMID:
28150070
26.

Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy.

Fall B, Scott CR, Mauer M, Shankland S, Pippin J, Jefferson JA, Wallace E, Warnock D, Najafian B.

PLoS One. 2016 Dec 16;11(12):e0168346. doi: 10.1371/journal.pone.0168346. eCollection 2016.

27.

Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes.

Ku E, McCulloch CE, Mauer M, Gitelman SE, Grimes BA, Hsu CY.

Diabetes Care. 2016 Dec;39(12):2218-2224.

28.

Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes.

Saulnier PJ, Wheelock KM, Howell S, Weil EJ, Tanamas SK, Knowler WC, Lemley KV, Mauer M, Yee B, Nelson RG, Beisswenger PJ.

Diabetes. 2016 Dec;65(12):3744-3753. Epub 2016 Sep 8.

29.

Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.

Hopkin RJ, Cabrera G, Charrow J, Lemay R, Martins AM, Mauer M, Ortiz A, Patel MR, Sims K, Waldek S, Warnock DG, Wilcox WR.

Mol Genet Metab. 2016 Sep;119(1-2):151-9. doi: 10.1016/j.ymgme.2016.06.007. Epub 2016 Jun 13.

30.

Development of Tract-Specific White Matter Pathways During Early Reading Development in At-Risk Children and Typical Controls.

Wang Y, Mauer MV, Raney T, Peysakhovich B, Becker BLC, Sliva DD, Gaab N.

Cereb Cortex. 2017 Apr 1;27(4):2469-2485. doi: 10.1093/cercor/bhw095.

31.

One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease.

Najafian B, Tøndel C, Svarstad E, Sokolovkiy A, Smith K, Mauer M.

PLoS One. 2016 Apr 15;11(4):e0152812. doi: 10.1371/journal.pone.0152812. eCollection 2016.

32.

Lower Oxytocin Plasma Levels in Borderline Patients with Unresolved Attachment Representations.

Jobst A, Padberg F, Mauer MC, Daltrozzo T, Bauriedl-Schmidt C, Sabass L, Sarubin N, Falkai P, Renneberg B, Zill P, Gander M, Buchheim A.

Front Hum Neurosci. 2016 Mar 30;10:125. doi: 10.3389/fnhum.2016.00125. eCollection 2016.

33.

Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives.

Moehler M, Delic M, Goepfert K, Aust D, Grabsch HI, Halama N, Heinrich B, Julie C, Lordick F, Lutz MP, Mauer M, Alsina Maqueda M, Schild H, Schimanski CC, Wagner AD, Roth A, Ducreux M.

Eur J Cancer. 2016 May;59:160-170. doi: 10.1016/j.ejca.2016.02.020. Epub 2016 Mar 31. Review.

34.

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.

Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, Hopkin RJ, Jovanovic A, Linhart A, Maruti SS, Mauer M, Oliveira JP, Patel MR, Politei J, Waldek S, Wanner C, Yoo HW, Warnock DG.

J Med Genet. 2016 Jul;53(7):495-502. doi: 10.1136/jmedgenet-2015-103486. Epub 2016 Mar 18.

35.

Predicting decline of kidney function in lupus nephritis using urine biomarkers.

Abulaban KM, Song H, Zhang X, Kimmel PL, Kusek JW, Nelson RG, Feldman HI, Vasan RS, Ying J, Mauer M, Nelsestuen GL, Bennett M, Brunner HI, Rovin BH.

Lupus. 2016 Aug;25(9):1012-8. doi: 10.1177/0961203316631629. Epub 2016 Feb 11.

36.

Structural Predictors of Loss of Renal Function in American Indians with Type 2 Diabetes.

Fufaa GD, Weil EJ, Lemley KV, Knowler WC, Brosius FC 3rd, Yee B, Mauer M, Nelson RG.

Clin J Am Soc Nephrol. 2016 Feb 5;11(2):254-61. doi: 10.2215/CJN.05760515. Epub 2016 Jan 20.

37.

The dose-response effect of insulin sensitivity on albuminuria in children according to diabetes type.

Mottl AK, Divers J, Dabelea D, Maahs DM, Dolan L, Pettitt D, Marcovina S, Imperatore G, Pihoker C, Mauer M, Mayer-Davis EJ; SEARCH for Diabetes in Youth Study.

Pediatr Nephrol. 2016 Jun;31(6):933-40. doi: 10.1007/s00467-015-3276-2. Epub 2016 Jan 11.

38.

The management and treatment of children with Fabry disease: A United States-based perspective.

Hopkin RJ, Jefferies JL, Laney DA, Lawson VH, Mauer M, Taylor MR, Wilcox WR; Fabry Pediatric Expert Panel.

Mol Genet Metab. 2016 Feb;117(2):104-13. doi: 10.1016/j.ymgme.2015.10.007. Epub 2015 Oct 23. Review.

PMID:
26546059
39.

Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983.

Tanis E, Julié C, Emile JF, Mauer M, Nordlinger B, Aust D, Roth A, Lutz MP, Gruenberger T, Wrba F, Sorbye H, Bechstein W, Schlag P, Fisseler A, Ruers T.

Eur J Cancer. 2015 Nov;51(17):2708-17. doi: 10.1016/j.ejca.2015.08.014. Epub 2015 Sep 2.

PMID:
26342674
40.

Podocyte structural parameters do not predict progression to diabetic nephropathy in normoalbuminuric type 1 diabetic patients.

Harindhanavudhi T, Parks A, Mauer M, Caramori ML.

Am J Nephrol. 2015;41(4-5):277-83. doi: 10.1159/000381992. Epub 2015 May 22.

41.

Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.

Wijburg FA, Bénichou B, Bichet DG, Clarke LA, Dostalova G, Fainboim A, Fellgiebel A, Forcelini C, An Haack K, Hopkin RJ, Mauer M, Najafian B, Scott CR, Shankar SP, Thurberg BL, Tøndel C, Tylki-Szymańska A, Ramaswami U.

PLoS One. 2015 May 8;10(5):e0124987. doi: 10.1371/journal.pone.0124987. eCollection 2015.

42.

Differential Response to High Glucose in Skin Fibroblasts of Monozygotic Twins Discordant for Type 1 Diabetes.

Caramori ML, Kim Y, Natarajan R, Moore JH, Rich SS, Mychaleckyj JC, Kuriyama R, Kirkpatrick D, Mauer M.

J Clin Endocrinol Metab. 2015 Jun;100(6):E883-9. doi: 10.1210/jc.2014-4467. Epub 2015 Apr 22.

43.

Differential Gene Expression in Diabetic Nephropathy in Individuals With Type 1 Diabetes.

Caramori ML, Kim Y, Goldfine AB, Moore JH, Rich SS, Mychaleckyj JC, Kirkpatrick D, Nickerson H, Krolewski AS, Mauer M.

J Clin Endocrinol Metab. 2015 Jun;100(6):E876-82. doi: 10.1210/jc.2014-4465. Epub 2015 Apr 14.

PMID:
25871838
44.

Cross-Disciplinary Biomarkers Research: Lessons Learned by the CKD Biomarkers Consortium.

Hsu CY, Ballard S, Batlle D, Bonventre JV, Böttinger EP, Feldman HI, Klein JB, Coresh J, Eckfeldt JH, Inker LA, Kimmel PL, Kusek JW, Liu KD, Mauer M, Mifflin TE, Molitch ME, Nelsestuen GL, Rebholz CM, Rovin BH, Sabbisetti VS, Van Eyk JE, Vasan RS, Waikar SS, Whitehead KM, Nelson RG; CKD Biomarkers Consortium.

Clin J Am Soc Nephrol. 2015 May 7;10(5):894-902. doi: 10.2215/CJN.11541114. Epub 2015 Mar 4. Review.

45.

Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus.

Fufaa GD, Weil EJ, Nelson RG, Hanson RL, Knowler WC, Rovin BH, Wu H, Klein JB, Mifflin TE, Feldman HI, Vasan RS, Kimmel PL, Kusek JW, Mauer M; CKD Biomarkers Consortium and the RASS Investigators.

Nephrol Dial Transplant. 2015 Apr;30(4):599-606. doi: 10.1093/ndt/gfv012. Epub 2015 Feb 3.

46.

Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis.

Kumagai K, Rouvelas I, Tsai JA, Mariosa D, Lind PA, Lindblad M, Ye W, Lundell L, Schuhmacher C, Mauer M, Burmeister BH, Thomas JM, Stahl M, Nilsson M.

Eur J Surg Oncol. 2015 Mar;41(3):282-94. doi: 10.1016/j.ejso.2014.11.039. Epub 2014 Nov 27. Review.

PMID:
25491892
47.

Effects of social exclusion on emotions and oxytocin and cortisol levels in patients with chronic depression.

Jobst A, Sabass L, Palagyi A, Bauriedl-Schmidt C, Mauer MC, Sarubin N, Buchheim A, Renneberg B, Falkai P, Zill P, Padberg F.

J Psychiatr Res. 2015 Jan;60:170-7. doi: 10.1016/j.jpsychires.2014.11.001. Epub 2014 Nov 10.

PMID:
25466833
48.

Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease.

Mauer M, Glynn E, Svarstad E, Tøndel C, Gubler MC, West M, Sokolovskiy A, Whitley C, Najafian B.

PLoS One. 2014 Nov 11;9(11):e112188. doi: 10.1371/journal.pone.0112188. eCollection 2014.

49.

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L.

Eur J Cancer. 2014 Nov;50(17):2983-93. doi: 10.1016/j.ejca.2014.07.011. Epub 2014 Sep 22. Review.

PMID:
25256896
50.

Glomerular structural-functional relationship models of diabetic nephropathy are robust in type 1 diabetic patients.

Mauer M, Caramori ML, Fioretto P, Najafian B.

Nephrol Dial Transplant. 2015 Jun;30(6):918-23. doi: 10.1093/ndt/gfu279. Epub 2014 Sep 1. Review.

Supplemental Content

Support Center